首页 › 多发性骨髓瘤 › 俄亥俄州 › Cincinnati
Cincinnati OH 多发性骨髓瘤临床试验
17项针对 多发性骨髓瘤的研究正在 Cincinnati及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
招募中3 期
- Research Site, Cincinnati
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
招募中3 期
- The Christ Hospital Cancer Center, Cincinnati
- Oncology Hematology Care, Cincinnati
- University of Cincinnati, Cincinnati
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- The Christ Hospital, Cincinnati
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
招募中2 期
- University of Cincinnati Medical Center, Cincinnati
- West Chester Hospital, West Chester · 距离 15 英里
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
招募中3 期
- University of Cincinnati Medical Center, Cincinnati
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中2 期
- Oncology Hematology Care, Cincinnati
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
招募中3 期
- TriHealth Cancer and Blood Institute, Cincinnati
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
招募中3 期
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- 以及另外 4 项
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
招募中3 期
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- 以及另外 1 项
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
招募中3 期
- Research Site, Cincinnati
- Research Site, Montgomery · 距离 11 英里
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
招募中1/2 期
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
招募中1 期
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
招募中3 期
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- 以及另外 2 项
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
招募中3 期
- University of Cincinnati, Cincinnati
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
招募中1 期
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
招募中2 期
- Oncology Hematology Care, Cincinnati
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
招募中1 期
- Oncology Hematology Care, Inc, Cincinnati
其他城市的 多发性骨髓瘤试验
- New York City, NY60 项研究
- Boston, MA42 项研究
- Atlanta, GA41 项研究
- Houston, TX38 项研究
- Durham, NC37 项研究
- Nashville, TN32 项研究
- Denver, CO26 项研究
- Columbus, OH24 项研究
- Baldwin Park, CA23 项研究
- St. Louis, MO23 项研究
- Rochester, MN23 项研究
- Washington, DC22 项研究
Cincinnati的其他研究
- 非小细胞肺癌35 项研究
- 癌症（所有类型）28 项研究
- 乳腺癌25 项研究
- 心力衰竭24 项研究
- 结直肠癌21 项研究
- 急性髓系白血病20 项研究
- 转移性癌症20 项研究
- 肺癌19 项研究
- 肥胖症19 项研究
- 卵巢癌19 项研究
- 前列腺癌18 项研究
- 黑色素瘤17 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年9月30日。每项研究自行设定入选标准，由研究团队决定谁能参与。